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Background: Invasive ductal carcinoma is the most common type of breast malignancy, with varying molecular
features and resistance to treatment. Although CD44+/CD24- cells are believed to act as breast cancer stem cells
and to be linked to poor prognosis in some patients, the association between these cells and tumor recurrence or
metastasis in all or some types of invasive ductal carcinoma is unclear.
Methods: A total of 147 randomly selected primary and secondary invasive ductal carcinoma samples were assayed
for expression of CD44, CD24, ER, PR, and Her2. The association between the proportions of CD44+/CD24- tumor
cells and the clinico-pathological features of these patients was evaluated.
Results: CD44+/CD24- tumor cells were detected in 70.1% of the tumors, with a median proportion of 5.8%.
The proportion of CD44+/CD24- tumor cells was significantly associated with lymph node involvement (P= 0.026)
and PR status (P= 0.038), and was correlated with strong PR status in patients with recurrent or metastatic tumors
(P= 0.046) and with basal-like features (p= 0.05). The median disease-free survival (DFS) of patients with and without
CD44+/CD24-/low tumor cells were 22.9 ± 2.2 months and 35.9 ± 3.8 months, and the median overall survival (OS) of
patients with and without CD44+/CD24-/low tumor cells were 39.3 ± 2.6 months and 54.0 ± 3.5 months, respectively,
and with both univariate and multivariate analyses showing that the proportion of CD44+/CD24-/low tumor cells
was strongly correlated with DFS and OS.
Conclusion: The prevalence of CD44+/CD24- tumor cells varied greatly in invasive ductal carcinomas, with the
occurrence of this phenotype high in primary tumors with high PR status and in secondary tumors. Moreover, this
phenotype was significantly associated with shorter cumulative DFS and OS. Thus, the CD44+/CD24- phenotype
may be an important factor for malignant relapse following surgical resection and chemotherapy in patients with
invasive ductal carcinoma.Introduction
Invasive ductal carcinoma is the most common breast
malignancy and a leading cause of cancer-related death
in women worldwide.[1] Despite developments in surgi-
cal methods, cytotoxic chemotherapy, and agents tar-
geted against estrogen receptor (ER) and HER2, a subset* Correspondence: pumclinyan@163.com
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reproduction in any medium, provided the orof patients with advanced stage invasive ductal carci-
noma may experience tumor recurrence or metastasis
within several years after treatment. It has been esti-
mated that 11% of women with invasive ductal carcin-
oma will experience a recurrence within five years after
surgery, including 8% of women with luminal A breast
cancers and 15% of women with tumors having basal-
like features.[2,3] The cancer stem cell hypothesis was
proposed to explore breast cancer heterogeneity and the
risk of breast cancer recurrence, and these cell subpopu-
lations may contribute to drug resistance that drives
tumor recurrence or metastasis [4].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and clinical characteristics of







Age (years) 50.8 ± 12.8 (13.0-77.0) 52.2 ± 12.4 (15.0-81.0) 0.510
Tumor size (cm) 3.2 ± 1.9 (1.2-9.5) 3.0 ± 1.6 (0.4-8.2) 0.437
Lymph node
involvement
45 (80.4%) 70 (76.9%) 0.624
TNM stages
I 5 (8.9%) 9 (9.9%) 0.511
II 24 (42.9%) 32 (35.2%)
III 27 (48.2%) 49 (53.8%)
IV 0 (0.0%) 1 (1.1%)
ER expression 26 (46.4%) 31 (34.1%) 0.168
PR expression 28 (50.0%) 36 (39.6%) 0.266
Her2 expression 29 (51.8%) 41 (45.1%) 0.471









ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal
growth factor receptor 2; IDC, Invasive ductal carcinoma.
* Immunohistochemically negative for both SR and Her2.
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cytometry analysis of cell surface markers such as CD44,
CD24, CD133, epithelial cell adhesion molecule, and
mucin-1,[5] normal human breast stem-cell like cells
have been independently identified as showing elevated
expression of CD44 and no expression of CD24 (CD44
+/CD24-), as well as elevated levels of stem cell enriched
genes.[6] The CD44+/CD24- subpopulation was believed
to be putative stem cells in human breast tissue,
enriched for basal cells and motility genes, which could
be generated during the epithelial-mesenchymal transi-
tion. Moreover, these cells were negative for mucin 1,
estrogen receptor (ER), and v-erb-b2 erythroblastic
leukemia viral oncogene homolog 2 (erbB2) receptor.
[7,8] More importantly, high expression of CD44
+/CD24- cancer cells was associated with poor patient
prognosis.[9] These cells had the phenotype of cancer
cells during the epithelial to mesenchymal transition,
[10] indicating that the gene expression pattern of CD44
+/CD24- cells in breast cancers resembled more closely
the pattern observed in CD44+/CD24- cells in normal
breast than that of CD44-/CD24+ cells isolated from the
same tumor.[6] Taken together, these findings indicated
that CD44+/CD24- cells, especially those expressing epi-
thelial cell adhesion molecule, were breast cancer stem
cells (CSCs).[11] In contrast, breast cancer cells expres-
sing elevated levels of aldehyde dehydrogenase 1
(ALDH1) were also described as breast CSCs, with
ALDH1+/CD44+/CD24- cells displaying strong tumori-
genic potential.[12] Moreover, breast CSCs were believed
to constitute up to 35% of the cancer cells in a tumor,
whereas these cells constituted only about 1% of stem
and progenitor cells present in normal breast [13].
Although CD44+/CD24- cells were regarded as breast
CSCs and to be linked with poor prognosis in some breast
cancer patients, the association between these cells and
tumor recurrence or metastasis in all or some patients with
breast cancer, especially those with invasive ductal carcin-
oma, has been unclear. Despite the fact that all intrinsic
subtypes of breast cancer have the same CSCs, tumor
relapse has been found to differ among patients with differ-
ent intrinsic subtypes of invasive ductal carcinoma. More-
over, although CD44+/CD24- breast cancer cells have
invasive properties, not all breast cancer cells with the
CD44+/CD24- phenotype were able to grow as metastatic
tumors whereas others showed aggressive metastatic
growth.[14] In addition, although some primary tumors
were predominantly CD44+, metastases at certain sites
lacked any CD44 expression. [10] We therefore investi-
gated whether breast cancer cells with the CD44+/CD24-
phenotype are associated with the metastasis of different
subtypes of invasive ductal carcinoma, and whether breast
cancer CD44+/CD24- cells possess essential characteristics
of cells with a metastatic phenotype.Materials and methods
Patients and specimens
A total of 147 invasive ductal carcinoma samples were
randomly selected from our tissue database. Patients
had been treated at the Peking Union Medical College
Hospital between April 2000 and December 2007. None
of these patients had received neoadjuvant chemotherapy
or radiotherapy. Clinical information was obtained by
reviewing preoperative and perioperative medical records,
or by telephone or written correspondence. Patients were
staged based on the tumor-node-metastases (TNM) clas-
sification of the International Union Against Cancer,
revised in 2002.[15] The use of these human materials in
this study was approved by the Peking Union Medical
College Hospital Medical Ethics Committee.
Patient clinical characteristics are shown in Table 1.
Fresh-frozen tumor tissue samples were used for routine
determination of estrogen receptor (ER), progestogen
receptor (PR), and human epidermal growth factor
receptor (Her2). Paraffin specimens of these tumors
were collected and 5 mm thick tissue sections were cut
and fixed onto silicified slides. Each sample was stained
Figure 1 Immunohistochemical staining for CD44, CD24, and
DAPI (×400).
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typed according to the World Health Organization
(WHO) classification [16]. Tumor size and the number
and location of metastatic lymph nodes were obtained
from pathology reports. Basal-like features of tumor was
defined as immunohistochemically negative for both SR
and Her2.
Immunohistochemical staining and evaluation
Briefly, each tissue section was deparaffinized, rehy-
drated and incubated with fresh 3% hydrogen peroxide
(H2O2) in methanol for 15 min. After rinsing with
phosphate-buffered saline (PBS), the samples were
immersed in 0.01 M sodium citrate buffer (pH 6.0) and
heated in a microwave oven at 100 °C for 15 min for
antigen retrieval. Non-specific binding was blocked by
incubating the sections with normal goat serum for
15 min at room temperature. The samples were subse-
quently incubated at 4 °C overnight with different pri-
mary antibodies. The primary antibodies used included
rabbit polyclonal antibody to CD44 (CD44v6, IgG, 1:50,
Abcam, Cambridge, UK), mouse monoclonal to CD24
(IgG, 1:50, Thermo Electron Corp., Burlington, ON,
CA), FITC linked mouse monoclonal antibody to SABC
(1:50), and goat anti-rabbit Cy3 antibody (IgG, 1:20).
CD44 was detected with permanent red and CD24 was
detected with diaminobenzidine. ALDH1 was detected
with a monoclonal rabbit anti-ALDH1 antibody
(ALDH1A1, IgG, 1:100, Abcam) followed by EnVision™
on a Tech-Mate™ (DAKO). All slides were counter-
stained with hematoxylin to identify nuclei. All samples
were scored twice by one person in a blinded fashion,
with all unclear results discussed with a pathologist. If
there were staining discrepancies among the three cores
from the same patient, an average was used. CD44 stain-
ing was detected mainly in the membrane and CD24
staining was detected mainly in the cytoplasm. The pro-
portion of CD44+/CD24- tumor cells was defined as the
percentage of cells positive for permanent red staining
but negative for diaminobenzidine staining. The results
of CD44+/CD24- tumor cells proportion were classified
into two groups, high and low, with a cut-off value based
on the median value of their proportion.
Statistical analysis
All calculations were performed using SPSS V.14.0 stat-
istical software (Chicago, IL, USA). Associations between
the presence of CD44, CD24 or different CD44/CD24
phenotypes and clinical variables as well as breast cancer
subgroups were assessed by Fisher's exact test, except
for age where the Mann–Whitney U test was used.
Multivariate analysis was performed using Cox propor-
tional hazards regression to determine the prognostic
effect on disease-free survival (DFS) and overall survival(OS), and the log-rank test to compare survival between
two strata. Hazard ratios (HR) and their corresponding
95% confidence intervals (CI) were computed to provide
quantitative information about the relevance of the
results of statistical analysis. All tests were two-sided
and P< 0.05 was considered statistically significant.Results
Patient characteristics
The baseline characteristics of the study population are
given in Table 1. All patients were female, with a mean ±
standard deviation (SD) age of 51.6 ± 12.5 years (range,
13.5 to 80.7 years) and a mean ± SD tumor size of
3.1 ± 1.8 cm (range, 0.4 to 9.5 cm). Lymph node involve-
ment was positive in 115 patients (78.2%). According
to TNM classification, 14 patients (9.5%) were stage I,
56 (38.1%) were stage II, 76 (51.7%) were stage III, and
1 (0.7%) was stage IV. Of the 147 patients, 57 (38.8%)
were positive for ER expression, 64 (43.5%) were positive
for PR, 70 (47.6%) were positive for Her2, and 39
(26.5%) were positive for basal-like features (defined as
immunohistochemically negative for both SR and Her2).
Of the 147 patients, 87 (59.2%) were received adjuvant
chemotherapy and 95 (64.6%) were received agents tar-
geted against estrogen receptor. Median follow-up time
was 23.0 months (range, 2 to 91 months), during which
40 patients (27.2%) experienced tumor recurrence and
51 (34.7%) developed metastases.
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carcinoma tissue
The presence of CD44 and CD24 antigens on invasive
ductal carcinoma tissues was analyzed using double-
staining immunohistochemistry. Figure 1 displays repre-
sentative staining patterns of CD44 and CD24. CD44
was visible primarily as membranous permanent red
staining, with only eight tumors displaying cytoplasmic
and membranous staining. CD24 was visible mainly as
cytoplasmic diaminobenzidine staining, with only six
tumors displaying membrane diaminobenzidine staining.
To determine the proportion of tumorigenic CD44Table 2 Proportion of all patients and patients with recurrenc
tumor cells
n All cases (%) P
Age (years)
< 50 74 18.34 ± 2.70 0
≥ 50 73 15.45 ± 2.66
Tumor size
T1 47 15.78 ± 2.86 0
T2 76 20.12 ± 2.90
T3 + T4 17 10.27 ± 4.46
Lymph node involvement
Absent 32 8.66 ± 2.70 0
Present 115 19.20 ± 2.29
TNM stage
I + II 70 15.87 ± 2.63 0
III + IV 77 18.49 ± 2.81
ER expression
Negative 90 16.49 ± 2.47 0
Positive 57 17.26 ± 3.07
PR expression
Negative 83 13.09 ± 2.41 0
Positive 64 21.06 ± 2.98
Her2 expression
Negative 77 16.18 ± 3.03 0
Positive 70 18.47 ± 2.61
Basal-like feature †
Absent 108 18.44 ± 2.24 0
Present 39 11.93 ± 3.66
Recurrence or metastasis
Absent 75 14.26 ± 2.72 0
Present 72 18.73 ± 2.58
Lesions in recurrence/metastatic patients
Primary
Secondary
* Calculated by t tests. ER, estrogen receptor; PR, progesterone receptor; Her2, hum
† Immunohistochemically negative for both SR and Her2.+/CD24- cells within each tumor, we scanned for the
presence of permanent red staining without any diami-
nobenzidine interference. CD44+/CD24- tumor cells
were present in 103 of the 147 (70.1%) tumors, but
absent from the other 44 (29.9%), with the proportion of
tumor cells expressing this phenotype ranging from a
few to 70%, with a median proportion of 5.8%, and this
median proportion was selected to categorize patients as
CD44+/CD24- tumor cells high group and CD44
+/CD24- tumor cells low group according to cutoff def-
inition. The frequency of tumors with different propor-





.444 34 24.91 ± 3.79 0.022
38 13.20 ± 3.32
.224 15 13.19 ± 3.53
44 23.78 ± 3.68
13 11.83 ± 6.60 0.152
.026 18 10.00 ± 3.77 0.075
54 21.53 ± 3.19
.500 33 16.88 ± 3.74 0.368
39 21.73 ± 3.79
.845 47 18.92 ± 3.17 0.944
25 19.32 ± 4.81
.038 43 14.63 ± 3.06 0.046
29 25.32 ± 4.51
.566 38 17.36 ± 4.17 0.441
34 21.57 ± 3.47
.143 49 11.70 ± 4.07 0.050
23 22.66 ± 3.30
.246
56 15.39 ± 2.63 0.014
16 30.41 ± 6.46
an epidermal growth factor receptor 2.
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in clinical specimens correlated significantly with lymph
node involvement (P= 0.026) and PR expression
(P= 0.038). Higher proportions of CD44+/CD24- tumor
cells were observed in specimens from patients with
(19.20%) than without (8.66%) lymph node involvement
and with (21.06%) than without (13.09%) PR expression.
There were no associations between percentage of CD44
+/CD24- tumor cells and patient age, tumor size, TNM
stages, ER or Her2 expression, and basal-like features.
Association of CD44+/CD24- phenotype with steroid
receptor status
Of the 121 samples with CD44/CD24 data, 56 (46.2%)
were positive for PR expression. CD44+/CD24- status
was significantly correlated with strong PR staining in
all patients (P= 0.038) and in samples from patients
with recurrence or metastasis (P= 0.046). Interestingly,
although ER expression was observed in 50 of the 121
(41.3%) patients with CD44/CD24 data, the presence ofTable 3 Univariate and multivariate analyses of the relationsh
Variable Univariate analysis
HR 95% CI p-va
CD44+/CD24-/low tumor cells
High 2.144 1.321-3.479 0.002
Low 1.000
ER status
Positive 0.826 0.524-1.304 0.412
Negative 1.000
PR status
Positive 0.500 0.312–0.800 0.004
Negative 1.000
Her2 status
Positive 0.966 0.614–1.521 0.882
Negative 1.000
Basal-like feature*
Present 2.731 0.461-1.393 0.007
Absent 1.000
TNM stage
Stage III/IV 1.989 0.814–2.626 0.029
Stage I/II 1.000
Lymph node involvement
Absent 0.724 0.427-1.227 0.230
Present 1.000
Age (years)
≥ 50 1.047 0.681–1.610 0.883
< 50 1.000
Abbreviations: HR, hazard ratio estimated from Cox proportional hazard regression
progesterone receptor; Her2, human epidermal growth factor receptor 2.
* Immunohistochemically negative for both SR and Her2.CD44+/CD24- tumor cells was not significantly corre-
lated with positive ER expression in all patients and in
patients with recurrence or metastasis.
Association of CD44+/CD24- phenotype with basal-like
feature
We found that the proportion of CD44+/CD24- tumor
cells was similar in breast cancer samples with and
without basal-like features (11.93% versus 18.44%,
p= 0.143). However, in samples from patients with
tumor recurrence or metastasis, the proportion of CD44
+/CD24- tumor cells was significantly higher in breast
cancer tissue with basal-like features than in tissue with-
out such features (22.66% versus 17.70%, p= 0.05).
Association of CD44+/CD24- phenotype with DFS and OS:
univariate analysis and multivariate analysis
The results of univariate analyses of the associations
between each individual predictor and DFS are shown in
Table 3. The proportion of CD44+/CD24-/low tumor cellsip of CD44+/CD24-/low tumor cells to disease-free survival
Multivariate analysis

















model; CI, confidence interval of the estimated HR. ER, estrogen receptor; PR,
Figure 2 (See legend on next page.)
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Figure 2 Analysis of disease-free survival (DFS) in breast cancer patients with and without the CD44+/CD24- phenotype. A. All patients;
B. Patients with invasive ductal carcinoma; C. Progesterone receptor (PR) negative patients; D. PR positive patients; E. Estrogen receptor (ER)
negative patients; F. ER positive patients; G. Her2 negative patients; H. Her2 positive patients; I. Patients with basal-like features; J. Patients not
receiving postoperative immunotherapy; K. Patients receiving postoperative immunotherapy.
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(P= 0.007), and TNM stage (P= 0.029) were strongly
correlated with DFS. Kaplan-Meier analysis showed
that the presence of CD44+/CD24-/low tumor cells was
significantly associated with shorter DFS compared
with the absence of CD44+/CD24-/low tumor cells
(22.9 ± 2.2 months versus 35.9 ± 3.8 months; Pearson
chi-square, 10.696, p = 0.001; Figure 2A). When all
predictors were included in a Cox model (multivariate
analysis, Table 3), the presence of CD44+/CD24-/low
tumor cells (hazard ratio, 1.931; P= 0.011), PR status,
basal-like feature, and TNM stage retained their prog-
nostic significance for DFS.
Meanwhile, the results of univariate analyses of the
associations between each individual predictor and OS
are shown in Table 4. Similarly with the relation with
DFS, the proportion of CD44+/CD24-/low tumor cells
(P= 0.001), basal-like feature (P= 0.029), and TNM stage
(P=0.027) were strongly correlated with OS. Kaplan-Meier
analysis showed that the presence of CD44+/CD24-/low
tumor cells was significantly associated with shorter OS
compared with the absence of CD44+/CD24-/low tumor
cells (39.3 ± 2.6 months versus 54.0± 3.5 months; Pearson
chi-square, 12.140, p=0.001). When all predictors were
included in a Cox model (multivariate analysis, Table 4),
the presence of CD44+/CD24-/low tumor cells (hazard
ratio, 2.237; P=0.002), basal-like feature, and TNM stage
retained their prognostic significance for OS.
Presence of CD44+/CD24- phenotype in secondary
invasive ductal carcinoma
We separately analyzed the secondary lesions from 56
patients with invasive ductal carcinoma and metastasis
or recurrence. We found that a significantly higher pro-
portion of secondary than primary lesions were positive
for CD44+/CD24-/low tumor cells (26.9% versus 7.0%,
P< 0.05).
Discussion
Invasive ductal carcinoma is the most common breast
malignancy in women, with relapse or metastasis fre-
quently occurring after surgical resection. CD44+/CD24-
breast cancer cells have been reported to have tumor-
initiating properties.[17,18] We therefore investigated
the importance of this breast CSC phenotype in the
relapse and metastasis of invasive ductal carcinoma cells.
Breast CSCs have been reported to constitute up to 35%
of cancer cells in a tumor, compared with approximately1% of stem and progenitor cells present in normal breast.
[13] However, the size of the CSC pool in breast cancers
is unclear, since one study showed that CSCs constitute
less than 10% of cells in 78% of breast tumors,[19]
whereas another study found that CD44+/CD24- cells
were present in all breast cancer samples. We therefore
determined the percentage of CD44+/CD24- cells in tis-
sue samples from 147 invasive ductal carcinomas. We
found that the size of the CSC pool ranged from 0% to
70%, with a median of 5.8%, and that CSCs constituted
less than 22% of the cells in 75% of primary tumors. In
contrast, tumor cells with this phenotype have been
reported in 31% of primary breast tumors. This discrep-
ancy may be due to different subtypes of breast cancers
and different percentages of samples from primary and
metastatic breast tumors.
Although CD44+/CD24- percentage was not asso-
ciated with ER or HER2 expression, we observed an as-
sociation between high CD44+/CD24- percentage and
PR expression. This linkage was more prominent in
samples from recurrent and metastatic tumors with
more than 25% CD44+/CD24- cells. In contrast, previous
studies showed that the presence of CD44+/CD24- tumor
cells was not associated with ER or PR status [20].
CD44+/CD24- cells have been observed in 63% of
basal-like subtype (SR-HER2- basal-like) breast tumors.
[20] Although we did not observe a significant difference
in the proportion of CD44+/CD24- cells in samples from
tumors with and without basal-like features, we found
that the CD44+/CD24- subpopulation was higher in
samples of recurrent and metastatic tumors with basal-
like features. Several studies have shown an association
between CD44+/CD24- cells and the metastasis of
basal-like breast cancers. For example, the expression of
several metastasis-associated genes was found to be higher
in cells with than without the CD44+/CD24- phenotype,
and only malignant cell lines with the CD44+/CD24- sub-
population were able to invade matrigel, indicating that
CD44+/CD24- cancer cells are more metastatic than non-
CD44+/CD24- cells [21,22].
Importantly, a unique 186-gene invasiveness gene sig-
nature has been observed in CD44+/CD24- malignant
cells,[22] linking the presence of CD44+/CD24- cells to
distant metastasis although not to survival.[8,23] We
found that the time to tumor relapse (including recur-
rence and metastasis) was significantly shorter in
patients with than without CD44+/CD24- tumor cells.
Metastasis is a complex process involving invasion,
Table 4 Univariate and multivariate analyses of the relationship of CD44+/CD24-/low tumor cells to overall survival
Variable Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
CD44+/CD24-/low tumor cells
High 2.193 1.383-3.477 0.001 2.237 1.345-3.720 0.002
Low 1.000 1.000
ER status
Positive 0.757 0.488-1.175 0.215 1.164 0.585-2.314 0.665
Negative 1.000 1.000
PR status
Positive 0.702 0.457–1.078 0.106 0.968 0.496–1.888 0.924
Negative 1.000 1.000
Her2 status
Positive 0.932 0.605–1.435 0.748 1.583 0.782–3.201 0.201
Negative 1.000 1.000
Basal-like feature*
Present 0.608 0.389-0.949 0.029 0.342 0.131-0.891 0.028
Absent 1.000 1.000
TNM stage
Stage III/IV 1.614 1.055–2.470 0.027 1.652 1.014–2.690 0.044
Stage I/II 1.000 1.000
Lymph node involvement
Absent 0.891 0.528-1.504 0.666 0.674 0.343-1.323 0.251
Present 1.000 1.000
Age (years)
≥ 50 1.110 0.735–1.676 0.621 1.384 0.847–2.260 0.194
< 50 1.000 1.000
Abbreviations: HR, hazard ratio estimated from Cox proportional hazard regression model; CI, confidence interval of the estimated HR. ER, estrogen receptor; PR,
progesterone receptor; Her2, human epidermal growth factor receptor 2.
* Immunohistochemically negative for both SR and Her2.
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and homing and proliferation at the sites of metastasis.
[8,24,25] The poor prognosis of patients with primary
tumors having higher levels of CD44+/CD24- cells, but
whose metastatic cells had the CD44±/CD24+ phenotype,
[26,27] suggests that CD44+/CD24- tumor cells may be a
transient phenotype and that these cells have an intrinsic
program to transition to a phenotype that enhances their
heterotypic interaction and survival/proliferation in distant
organs.[8] This hypothesis, however, cannot explain the dif-
ference in time to tumor relapse in patients with and with-
out CD44+/CD24- cancer cells who had undergone surgical
resection plus immunotherapy.
Conclusion
We observed variations in the prevalence of CD44+/CD24-
tumor cells in breast tumors of different subtypes. This
phenotype was highly prevalent in primary tumors with
high PR expression and in secondary tumors. These
results provide further evidence for the biologicalheterogeneity of breast cancers and for the enrichment
in putative tumor-initiating cells in tumors with high PR
expression and in secondary tumors. Moreover, the pres-
ence of CD44+/CD24-/low tumor cells was associated
with a shorter cumulative DFS and OS, suggesting that
the CD44+/CD24- phenotype may be an important factor
of malignant relapse in patients with surgically resected
invasive ductal carcinoma after chemotherapy.
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